Skip to content

Study · Measured the body's own peptide · 1982

4 results

Vasoactive intestinal peptide (VIP) in preterm and term neonates.

Lucas A, Bloom SR, Aynsley-Green A

Acta paediatrica Scandinavica1 Jan 1982Cited by 5 (Europe PMC)

PMID7136620 (opens in a new tab)DOI10.1111/j.1651-2227.1982.tb09373.x (opens in a new tab)PepBankPUB-07136620
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Plasma VIP concentrations did not change after a feed in any of the neonate groups.

    In plain wordsIn newborn babies, the body's own VIP level in blood did not change after a feed.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma VIP change after a feed
    Study

    n = 257

    Comparator
    Pre-feed level
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    Plasma VIP concentrations did not change following a feed in any of the groups of neonates studied.
    1 context sentence
    Summary · context
    We have measured plasma concentrations of this biologically important peptide in 159 preterm infants and 98 term neonates.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Preterm neonates in the first four days of life had plasma VIP concentrations about five times higher than healthy adults, and the high levels persisted through the neonatal period.

    In plain wordsPreterm babies had about five times more of the body's own VIP in blood than healthy adults.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma VIP in preterm neonates versus adults
    Study

    n: not reported in source

    Comparator
    Healthy adult controls
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    Plasma VIP
    9.6 pmol/l
    preterm neonates, first four days
    Plasma VIP
    1.9 pmol/l
    healthy adult controls

    Source sentences

    Summary
    Preterm neonates during the first four days of life had plasma VIP concentrations which were five times greater than the levels in 12 healthy adult controls (9.6+/-0.7 pmol/l, mean +/-S.E.M., compared with 1.9+/-0.5 pmol/l, p less than 0.001), and these elevated concentrations persisted throughout the neonatal period.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Term infants on the sixth day of life had plasma VIP concentrations about half those of preterm infants of the same postnatal age.

    In plain wordsTerm babies at six days had about half the body's own VIP in blood compared with preterm babies of the same age.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePlasma VIP in term versus preterm infants at day six
    Study

    n: not reported in source

    Comparator
    Preterm infants of the same age
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    In contrast term infants on the sixth day of life, had plasma VIP concentrations only half those seen in preterm infants on the same post natal age (p less than 0.001).
    1 context sentence
    Summary · context
    We have measured plasma concentrations of this biologically important peptide in 159 preterm infants and 98 term neonates.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Bottle-fed term infants had higher plasma VIP levels than breast-fed term infants.

    In plain wordsBottle-fed term babies had more of the body's own VIP in blood than breast-fed term babies.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma VIP in bottle-fed versus breast-fed term infants
    Study

    n: not reported in source

    Comparator
    Breast-fed term infants
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    Plasma VIP
    5.6 pmol/l
    bottle-fed term infants
    Plasma VIP
    4.3 pmol/l
    breast-fed term infants

    Source sentences

    Summary
    Bottle-fed term infants had higher VIP levels than those who were breast fed (5.6+/-0.4 vs. 4.3+/-0,4, p less than 0.05).
    1 context sentence
    Summary · context
    We have measured plasma concentrations of this biologically important peptide in 159 preterm infants and 98 term neonates.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.